Literature DB >> 20489186

Blinded independent central review of the progression-free survival endpoint.

Ohad Amit1, Will Bushnell, Lori Dodd, Nancy Roach, Daniel Sargent.   

Abstract

Mesh：

Year:  2010        PMID： 20489186      PMCID： PMC3227978          DOI： 10.1634/theoncologist.2009-0261

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  2 in total

1.  Proposal for the use of progression-free survival in unblinded randomized trials.

Authors:  Boris Freidlin; Edward L Korn; Sally Hunsberger; Robert Gray; Scott Saxman; Jo Anne Zujewski
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

Review 2.  Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Authors:  Lori E Dodd; Edward L Korn; Boris Freidlin; C Carl Jaffe; Lawrence V Rubinstein; Janet Dancey; Margaret M Mooney
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544
  2 in total
  12 in total

1.  Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.

Authors:  Yingwei Qi; Katie L Allen Ziegler; Shauna L Hillman; Mary W Redman; Steven E Schild; David R Gandara; Alex A Adjei; Sumithra J Mandrekar
Journal:  Cancer       Date:  2012-03-20       Impact factor: 6.860

2.  PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question.

Authors:  A Gallamini; M Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-12       Impact factor: 9.236

3.  Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.

Authors:  Vadim S Koshkin; Vanessa Bolejack; Lawrence H Schwartz; Richard L Wahl; Rashmi Chugh; Denise K Reinke; Binsheng Zhao; Joo H O; Shreyaskumar R Patel; Scott M Schuetze; Laurence H Baker
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

4.  On robustness of noninferiority clinical trial designs against bias, variability, and nonconstancy.

Authors:  Qing Liu; Yulan Li; Katherine Odem-Davis
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

5.  A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer.

Authors:  Yunpeng Yang; Jianhua Chang; Cheng Huang; Yiping Zhang; Jie Wang; Yongqian Shu; Jean Philippe Burillon; Marcello Riggi; Aurélie Petain; Pierre Ferre; Ying Liang; Li Zhang
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

6.  Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years.

Authors:  Jianrong Zhang; Yiyin Zhang; Shiyan Tang; Hengrui Liang; Difei Chen; Long Jiang; Qihua He; Yu Huang; Xinyu Wang; Kexin Deng; Shuhan Jiang; Jiaqing Zhou; Jiaxuan Xu; Xuanzuo Chen; Wenhua Liang; Jianxing He
Journal:  Ann Transl Med       Date:  2017-12

7.  Commentary: tackling the challenges of developing targeted therapies for cancer.

Authors:  Richard L Schilsky; Jeff Allen; Joshua Benner; Ellen Sigal; Mark McClellan
Journal:  Oncologist       Date:  2010

Review 8.  Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?

Authors:  Marilyn C Pike; Lexy Kelley
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 9.  Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab.

Authors:  Harris Ahmad; Tyler M Berzin; Hui Jing Yu; Christopher S Huang; Daniel S Mishkin
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-07-03

Review 10.  Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour.

Authors:  Jianrong Zhang; Yiyin Zhang; Shiyan Tang; Long Jiang; Qihua He; Lindsey Tristine Hamblin; Jiaxi He; Zhiheng Xu; Jieyu Wu; Yaoqi Chen; Hengrui Liang; Difei Chen; Yu Huang; Xinyu Wang; Kexin Deng; Shuhan Jiang; Jiaqing Zhou; Jiaxuan Xu; Xuanzuo Chen; Wenhua Liang; Jianxing He
Journal:  BMJ Open       Date:  2018-09-10       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.